✦ LIBER ✦

Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome

✍ Scribed by Pier Luigi Zinzani; Letizia Gandolfi; Vittorio Stefoni; Stefano Fanti; Mariapaola Fina; Cinzia Pellegrini; Gian Carlo Montini; Enrico Derenzini; Alessandro Broccoli; Lisa Argnani; Stefano Pileri; Michele Baccarani

Book ID: 119936259
Publisher: Elsevier
Year: 2010
Tongue: English
Weight: 183 KB
Volume: 10
Category: Article
ISSN: 2152-2650
DOI: 10.3816/clml.2010.n.054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Weight-Based Dosing of Yttrium 90 Ibritu

Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

✍ Wiseman, Gregory A.; Conti, Peter S.; Vo, Katie; Schilder, Russell J.; Gordon, L 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 106 KB

A randomized study comparing yttrium-90

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

✍ Avichai Shimoni; Irit Avivi; Jacob M. Rowe; Moshe Yeshurun; Itai Levi; Reuven Or 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

The city of hope experience with novel t

The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

✍ A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 56 KB